US CDC report: vacc levels at record highs

9 September 2007

The US Centers for Disease Control and Prevention (CDC) has published an analysis of child immunization levels, recording variations by age and geography. The federal agency found that young children are at record immunization levels but these lag behind government targets. The full report was published in the September 1 edition of the CDC's Morbidity and Mortality Weekly Report.

In 2006, the CDC states that 77% of US children aged 19-35 months received six vaccines against 10 diseases: diphteria; tetanus; pertussis; polio; measles; mumps; rubella; hemophilius; hepatitis B; and chickenpox. However, the level is well below the target set for 2010 of achieving 90% coverage in this age group and is similar to the proportion recorded in a 2005 survey.

The highest ranked states tended to be along the eastern seaboard, with Massachusetts seeing 83.6% of young children receiving all six courses of immunization. Apart from West Virginia (68.4%), one of the poorest states, the lowest coverage rates were found to the west of the Mississippi river, with Nebraska (59.5%) trailing behind the second-lowest performer, Wyoming (63.5%), by some distance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight